Business Context and Reporting Period
Tuhura Biosciences, Inc. (Nasdaq: HURA) filed a Current Report on Form 8-K dated December 2, 2025. The filing details an amendment to a Secured Promissory Note and Loan Agreement previously entered into on October 27, 2025, with the Matthew Nachtrab Revocable Trust dated 12/18/2014.
Key Financial Metrics and Transaction Details
- Total Debt Obligation: The Company has borrowed an aggregate principal amount of $3.0 million under the Loan Agreement.
- Recent Borrowing: An additional $1.5 million (the "Second Loan") was advanced on December 2, 2025, following an initial $1.5 million advance (the "First Loan").
- Equity Issuance: The Company issued warrants to purchase an aggregate of 234,783 shares of common stock.
- Warrant Terms: The warrants have an exercise price of $1.81 per share (based on the closing price on the issuance date) and expire two years from issuance.
- Liquidity: The filing does not provide specific cash balance or liquidity metrics beyond the debt transaction details.
Material Changes
The primary material change is the extension of the loan availability period to December 5, 2025, and the clarification of warrant issuance terms. Specifically, the amendment established that the Lender receives a warrant to purchase 150,000 shares for each $1.5 million borrowed, prorated for smaller amounts. This resulted in the full $3.0 million credit facility being utilized and the issuance of the additional warrant tranche.
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure of the new financial obligation. The transaction creates a direct financial obligation and an off-balance sheet arrangement (warrants) as noted in Item 2.03.
Investor Verification Checklist
- Verify the full text of the Amendment to Secured Promissory Note and Loan Agreement (Exhibit 10.1) for interest rates, maturity dates, and covenants not summarized in the 8-K.
- Confirm the dilution impact of the 234,783 warrants issued at an exercise price of $1.81.
- Review the Company's most recent 10-K or 10-Q to assess current cash reserves against the new $3.0 million debt obligation.
- Check for any subsequent filings regarding the repayment schedule or further drawdowns after the December 5, 2025 availability deadline.